The Food and Drug Administration is on a roll. America’s drug regulator recently
approved
Veopoz as the first treatment for Chaple disease, a very rare inherited immune condition. The FDA also
gave full approval
to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial data. And agency officials
green-lit the first vaccine
to protect infants from respiratory syncytial virus.
With all of these approvals, the FDA is
on track
to approve more novel drugs by the end of September than it did for
all of 2022
. But challenges remain, and the FDA stubbornly clings onto a regulatory model grounded in risk aversion. It’s time for the agency to embrace its winning streak and keep innovation in the driver’s seat.
CALIFORNIA IS GROUND ZERO FOR RETAIL THEFT PROSECUTION CONTROVERSY
Like many…
